Microbiome Derived Metabolism and Pharmacokinetics
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The investigators will perform single-dose pharmacokinetic (PK) studies in humans following
administration of drugs with known microbiome derived metabolism (MDM) in parallel with
preclinical studies. By directly comparing laboratory measurements to clinical results, the
investigators will be able to confirm the relevance of MDM in vivo, create
microbiome-dependent PK profiles of the MDM positive drugs, and establish methodology to
capture the contribution of MDM to inter-individual variability in clinical drug PK profiles.